Zusammenfassung
Die Elektrokonvulsionstherapie (EKT) wirkt bei klinisch heterogenen Syndromen: Neben antidepressiven, antimanischen, antipsychotischen, antikonvulsiven, antisuizidalen, stimmungsstabilisierenden und antikatatonen Eigenschaften wurden positive Effekte auf motorische Symptome des Morbus Parkinson beschrieben. Eine umfassende Theorie des Wirkmechanismus existiert bislang noch nicht. In human- und tierexperimentellen Studien mit EKT bzw. ECS, dem Tiermodell der EKT, konnten jedoch Veränderungen verschiedener potenziell antidepressiv wirksamer Hormone, Neurotransmitter und ihrer Rezeptoren, verschiedener Neuropeptide und neurotropher Faktoren festgestellt werden. Zudem konnten eine EKT-bedingte kurzzeitige Öffnung der Blut-Hirn-Schranke und eine Zunahme des zerebralen Blutflusses nachgewiesen werden. Mittels Bildgebung konnten eine teilweise Normalisierung von Fasertraktanomalien sowie eine Normalisierung der funktionellen Konnektivität depressiver Patienten durch EKT gezeigt werden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Abrams R, Swartz CM (1985) Electroconvulsive therapy and prolactin release: Relation to treatment response in melancholia. Convuls Ther 1: 38–42
Adams HE, Hoblit PR, Sutker PB (1968) Electroconvulsive shock, brain acetylcholinesterase activity and memory. Physiol Behav 4: 113–116
Altar CA, Whitehead RE, Chen R et al (2003) Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 54: 703–709
Altar CA, Laeng P, Jurata LW (2004) Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24: 2667–2677
Barkai AI, Durkin M, Nelson HD (1990) Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: an autoradiographic study. Brain Res 529: 208–213
Biegon A, Israeli M (1986) Localization of the effects of electroconvulsive shock on ß-Adrenoreceptors in the rat brain. European J Pharmacol 123: 329–334
Blendy JA, Perry DC, Pabreza LA, Kellar KJ (1991) Electroconvulsive shock increases alpha 1b- but not alpha 1a-adrenoceptor binding sites in rat cerebral cortex. J Neurochem 57: 1548–1555
Bocchio-Chiavetto L, Zanardini R, Bortolomasi M et al (2006) Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 16: 620–624
Bonne O, Krausz Y, Shapira B et al (1996) Increased cerebral blood flow in depressed patients responding to electroconvulve therapy. J Nucl Med 37: 1075–1080
Calker D van, Biber K (2005) The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders. Neurochem Res 30: 1205–1217
Cassidy F, Weiner RD, Cooper TD, Carroll BJ (2010) Combined catecholamine and indoleamine depletion following response to ECT. Br J Psychiatry 196: 493–494
Coffey CE, Lucke J, Weiner RD et al (1995) Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT. Biol Psychiatry 37: 777–788
Devanand DP, Shapira B, Petty F et al (1995) Effects of electroconvulsive therapy on plasma GABA. Convuls Ther 11: 3–13
Du MY, Wu QZ, Yue Q et al (2012) Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 36: 11–16
Elfving B, Wegener G (2012) Electroconvulsive seizures stimulate the VEGF pathway via mTORC1. Synapse 66: 340–345
Esel E, Kose K, Hacimusalar Y et al (2008) The effects of electroconvulsive therapy on GABAergic function in major depressive patients. J ECT 24: 224–228
Florkowski CM, Crozier IG, Nightingale S et al (1996) Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy. Clin Endocrinol (Oxf) 44: 163–168
Fochtmann LJ, Cruciani R, Aiso M, Potter WZ (1989) Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra. Eur J Pharmacol 167: 305–306
Förstl H, Hautzinger M, Roth G (2006) Neurobiologie psychischer Störungen. Springer, Heidelberg
Folkerts H (1996) The ictal electroencephalogram as a marker for the efficacy of electroconvulsive therapy. Eur Arch Psychiatry Clin Neurosci 246: 155–164
Garcia-Garcia L, Llewellyn-Jones V, Fernandez Fernandez I et al (1998) Acute and repeated ECS treatment increases CRF, POMC and PENK gene expression in selected regions of the rat hypothalamus. Neuroreport 9: 73–77
Glue P, Costello MJ, Pert A et al (1990) Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl) 100: 60–65
Gray JA, Green AR (1987) Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks. Br J Pharmacol 92: 357–362
Gur E, Dremencov E, Garcia F et al (2002) Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 952: 52–60
Hayakawa H, Shimizu M, Nishida A et al (1994) Increase in serotonin 1A receptors in the dentate gyrus as revealed by autoradiographic analysis following repeated electroconvulsive shock but not imipramine treatment. Neuropsychobiology 30: 53–56
Hofmann P, Loimer N, Chaudhry HR et al (1996) 5-Hydroxy-indolacetic-acid (5-HIAA) serum levels in depressive patients and ECT. J Psychiat Res 30: 209–216
Holsboer F (2000) The corticosteroid rezeptor hypothesis of depression. Neuropsychopharmacology 23: 477–501
Hosoda K, Duman RS (1993) Regulation of beta 1-adrenergic receptor mRNA and ligand binding by antidepressant treatments and norepinephrine depletion in rat frontal cortex. J Neurochem 60: 1335–1343
Jacobsen JP, Mørk A (2004) The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024: 183–192
Jiménez-Vasquez PA, Diaz-Cabiale Z, Caberlotto L et al (2007) Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur Neuropsychopharmacol 17: 298–308
Kang I, Miller LG, Moises J, Bazan NG (1991) GABAA receptor mRNAs are increased after electroconvulsive shock. Psychopharmacol Bull 27: 359–363
Kling MA, Geracioti TD, Licinio J et al (1994) Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. Psychopharmacol Bull 30: 489–494
Kondratyev A, Ved R, Gale K (2002) The effects of repeated minimal electroconvulsive shock exposure on levels of mRNA encoding fibroblast growth factor-2 and nerve growth factor in limbic regions. Neuroscience 114: 411–416
Kronfol Z, Hamdan-Allen G, Goel K, Hill EM (1991) Effects of single and repeated electroconvulsive therapy sessions on plasma ACTH, prolactin, growth hormone and cortisol concentrations. Psychoneuroendocrinology 16: 345–352
Lammers CH, Diaz J, Schwartz JC, Sokoloff P (2000) Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5: 378–388
Liao Y, Huang X, Wu Q et al (2013) Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. J Psychiatry Neurosci 38: 49–56
Ma XM, Mains RE, Eipper BA (2002) Plasticity in hippocampal peptidergic systems induced by repeated electroconvulsive shock. Neuropsychopharmacology 27: 55–71
Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104–9110
Mann JJ (1998) Neurobiological correlates of the antidepressant action of electroconvulsive therapy. J ECT 14: 172–180
Mann JJ, Kapur S (1994) Elucidation of biochemical basis of the antidepressant action of electroconvulsive therapy by human studies. Psychopharmacol Bull 30: 445–453
Mathé AA (1999) Neuropeptides and electroconvulsive treatment. J ECT 15: 60–75
McGarvey KA, Zis AP, Brown EE et al (1993) ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry 34: 152–157
Minelli A, Zanardini R, Abate M et al (2011) Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 35: 1322–1325
Morinobu S, Nibuya M, Duman RS (1995) Chronic antidepressant treatment down-regulates the induction of c-fos mRNA in response to acute stress in rat frontal cortex. Neuropsychopharmacology 12: 221–228
Naylor P, Stewart CA, Wright SR et al (1996) Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res Mol Brain Res 35: 349–353
Nemeroff CB, Bissette G, Akil H, Fink M (1991) Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotropin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158: 59–63
Newton SS, Collier EF, Hunsberger J et al (2003) Gene profile of electroconvulsive seizures: Induction of neurotrophic and angiogenetic factors. J Neurosci 23: 10841–10851
Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539–7547
Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16: 2365–2372
Nikisch G, Mathé AA (2008) CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 23: 356–359
Nobler MS, Sackeim HA, Prohovnik I et al (1994) Regional cerebral blood flow in mood disorders, III. Treatment and clinical response. Arch Gen Psychiatry 51: 884–897
Nobuhara K, Okugawa G, Minami T et al (2004) Effects of electroconvulsive therapy on frontal white matter in late-life depression: a diffusion tensor imaging study. Neuropsychobiology 50: 48–53
Okamoto T, Yoshimura R, Ikenouchi-Sugita A et al (2008) Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 32: 1185–1190
Ottosson J-O (1960) Experimental studies of the mode of action of electroconvulsive therapy. Acta Psychiatr Scand 145 (Suppl): 1–141
Pandey SC, Isaac L, Davis JM, Pandey GN (1991) Similar effects of treatment with desipramine and electroconvulsive shock on 5-hydroxytryptamine1A receptors in rat brain. Eur J Pharmacol 202: 221–225
Pandey GN, Pandey SC, Isaac L, Davis JM (1992) Effect of electroconvulsive shock on 5-HT2 and alpha 1-adrenoceptors and phosphoinositide signalling system in rat brain. Eur J Pharmacol 226: 303–310
Perera TD, Coplan JD, Lisanby SH et al (2007) Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 27: 4894–4901
Perrin JS, Merz S, Bennett DM et al (2012) Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder. Proc Natl Acad Sci U S A 109: 5464–5468
Pfleiderer B, Michael N, Erfurth A et al (2003) Effective electronconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 122: 185–192
Piccinni A, Del Debbio A, Medda P et al (2009) Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 19: 349–355
Preskorn SH, Irwin GH, Simpson S et al (1981) Medical therapies for mood disorders alter the blood-brain barrier. Science 213: 469–471
Riddle WJ, Scott AI, Bennie J et al (1993) Current intensity and oxytocin release after electroconvulsive therapy. Biol Psychiatry 33: 839–841
Rudorfer MV, Risby ED, Osman OT et al (1991) Hypothalamic-pituitary-adrenal axis and monoamine transmitter activity in depression: a pilot study of central and peripheral effects of electroconvulsive therapy. Biol Psychiatry 29: 253–264
Sackeim HA (1994) Central issues regarding the mechanisms of action of electroconvulsive therapy: directions for future research. Psychopharmacol Bull 30: 281–308
Sackeim HA, Devanand DP, Prudic J (1991) Stimulus intensity, seizure threshold, and seizure duration: impact on the efficacy and safety of electroconvulsive therapy. Psychiatr Clin North Am 14: 803–843
Sadek AR, Knight GE, Burnstock G (2011) Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling. Purinergic Signal 7, 447–452
Saijo T, Takano A, Suhara T et al (2010) Electroconvulsive therapy decreases dopamine D2receptor binding in the anterior cingulate in patients with depression: a controlled study using positron emission tomography with radioligand [11¹C]FLB 457. J Clin Psychiatry 71: 793–799
Sanacora G, Mason GF, Rothman DL et al (2003) Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 160: 577–579
Santarelli L, Saxe M, Gross C et al (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805–809
Sattin A (1999) The role of TRH and related peptides in the mechanism of action of ECT. J ECT 15: 76–92
Scott AI, Douglas RH, Whitfield A, Kendell RE (1990) Time course of cerebra; magnetic resonance changes after electroconvulsive therapy. Br J Psychiatry 156: 551–553
Smith S, Lindefors N, Hurd Y, Sharp T (1995) Electroconvulsive shock increases dopamine D1 and D2 receptor mRNA in the nucleus accumbens of the rat. Psychopharmacology (Berl) 120: 333–340
Strome EM, Clark CM, Zis AP, Doudet DJ (2005) Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F] setoperone. Biol Psychiatry 57: 1004–1010
Takano H, Motohashi N, Uema T et al (2007) Changes in regional cerebral blood flow during acute electroconvulsive therapy in patients with depression: positron emission tomographic study. Br J Psychiatry 190: 63–68
Tang SW, Helmeste D, Leonard B (2012) Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J Biol Psychiatry 13: 402–412
Tortella FC, Long JB (1988) Characterization of opioid peptide-like anticonvulsant activity in rat cerebrospinal fluid. Brain Res 456: 139–146
Watkins CJ, Pei Q, Newberry NR (1998) Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res Mol Brain Res 61: 108–113
Weizman A, Gil-Ad I, Grupper D et al (1987) The effect of acute and repeated electroconvulsive treatment on plasma beta-endorphin, growth hormone, prolactin and cortisol secretion in depressed patients. Psychopharmacology 93: 122–126
Winston SM, Hayward MD, Nestler EJ, Duman RS (1990) Chronic electroconvulsive seizures down-regulate expression of the immediate-early genes c-fos and c-jun in rat cerebral cortex. J Neurochem. 54: 1920–1925
Yatham LM, Liddle PF, Lam RW et al (2010) Effect of electroconvulsive therapy on brain 5-HT2 receptors in major depression. Br J Psychiatry 196: 474–497
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Janouschek, H., Nickl-Jockschat, T. (2013). Wirkungsmechanismen der EKT. In: Grözinger, M., Conca, A., Nickl-Jockschat, T., Di Pauli, J. (eds) Elektrokonvulsionstherapie kompakt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-25629-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-25629-5_14
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-25628-8
Online ISBN: 978-3-642-25629-5
eBook Packages: Medicine (German Language)